ADRUCIL 50 MG
FLUOROURACIL : 50 MG · DIN 02063921 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is ADRUCIL?
ADRUCIL 50 MG contains FLUOROURACIL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02063921, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 08-Apr-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is ADRUCIL called?
The same molecule, FLUOROURACIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Fluorouracil Accord | Latin | Australia |
| Tolak | Latin | Norway |
| Efudix | Latin | Australia, South Africa |
| Actikerall | Latin | Norway |
| FLUORO URACILE ICN | Latin | Morocco |
| FLUOROURACIL EBEWE | Latin | Morocco |
| Fluorouracil Viatris | Latin | Australia |
| FLUOROURACILE MYLAN | Latin | Morocco |
| PHARMAURACIL | Latin | Morocco |
| Verrumal® | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02063921 |
|---|---|
| Brand name | ADRUCIL |
| Generic / active ingredient | FLUOROURACIL : 50 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 50 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01BC02 FLUOROURACIL |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 08-Apr-2004 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02063921 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2063921 |
| Brand name | ADRUCIL |
| Active ingredient / INN | FLUOROURACIL : 50 MG |
| ATC code | L01BC02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
Which pack is which?
| Strength on the label | 50 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code L01BC02 FLUOROURACIL. 6 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EFUDEX | 5 % | CREAM | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00330582 |
| FLUOROURACIL INJECTION | 0.5 G / 10 ML | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | DIN 02473763 |
| FLUOROURACIL INJECTION | 5 G / 100 ML | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | DIN 02473771 |
| FLUOROURACIL INJECTION | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00012882 |
| FLUOROURACIL INJECTION USP | 50 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02413450 |
| TOLAK | 4 % | CREAM | HILL DERMACEUTICALS INC | MARKETED | DIN 02485346 |
| ADRUCIL INJ 50MG/ML | 500 MG / 10 ML | LIQUID | ADRIA LABORATORIES OF CANADA LTD. | CANCELLED POST MARKET | DIN 00428493 |
| FLUOROPLEX CREAM 1% | 1 % | CREAM | ALLERGAN HERBERT SKIN CARE DIVISION OF ALLERGAN INC. | CANCELLED POST MARKET | DIN 01982311 |
| FLUOROURACIL INJ 50MG/ML | 50 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 00891754 |
| FLUOROURACIL INJECTION | 1000 MG / 20 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | APPROVED | DIN 02476746 |
Who else supplies FLUOROURACIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUOROURACIL appears in 63 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does FLUOROURACIL cost around the world?
FLUOROURACIL is listed on 11 national price registers Nexara tracks, across 65 pack listings published on 10 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 11 | 15 | 01 Sep 2026 |
| United States | acquisition | 4 | 10 | 03 Sep 2026 |
| Australia | ex-manufacturer | 6 | 9 | 08 Sep 2026 |
| United Kingdom | hospital | 6 | 6 | 31 Aug 2026 |
| Morocco | PPV (public price) | 5 | 5 | 05 Sep 2026 |
| Romania | max producer price | 1 | 5 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 2 | 4 | 07 Sep 2026 |
| South Africa | single exit price | 3 | 4 | 01 Sep 2026 |
| United Arab Emirates | public | 3 | 3 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.